These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 32837219)

  • 1.
    Gurung AB; Ali MA; Lee J; Abul Farah M; Al-Anazi KM
    Saudi J Biol Sci; 2020 Oct; 27(10):2674-2682. PubMed ID: 32837219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme.
    Bahadur Gurung A; Ajmal Ali M; Lee J; Abul Farah M; Mashay Al-Anazi K
    J King Saud Univ Sci; 2020 Sep; 32(6):2845-2853. PubMed ID: 32837113
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
    Wang YC; Yang WH; Yang CS; Hou MH; Tsai CL; Chou YZ; Hung MC; Chen Y
    Am J Cancer Res; 2020; 10(8):2535-2545. PubMed ID: 32905393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and Cleavage of Middle East Respiratory Syndrome Coronavirus nsp3-4 Polyprotein Induce the Formation of Double-Membrane Vesicles That Mimic Those Associated with Coronaviral RNA Replication.
    Oudshoorn D; Rijs K; Limpens RWAL; Groen K; Koster AJ; Snijder EJ; Kikkert M; Bárcena M
    mBio; 2017 Nov; 8(6):. PubMed ID: 29162711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Saudi J Biol Sci; 2021 Feb; 28(2):1426-1432. PubMed ID: 33281478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.
    Odhar HA; Ahjel SW; Albeer AAMA; Hashim AF; Rayshan AM; Humadi SS
    Bioinformation; 2020; 16(3):236-244. PubMed ID: 32308266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational modeling of the bat HKU4 coronavirus 3CL
    Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
    J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.
    Ahmad J; Ikram S; Ahmad F; Rehman IU; Mushtaq M
    Heliyon; 2020 Jul; 6(7):e04502. PubMed ID: 32754651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based drug designing towards the identification of potential anti-viral for COVID-19 by targeting endoribonuclease NSP15.
    Krishnan DA; Sangeetha G; Vajravijayan S; Nandhagopal N; Gunasekaran K
    Inform Med Unlocked; 2020; 20():100392. PubMed ID: 32835078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
    Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection.
    De P; Kumar V; Kar S; Roy K; Leszczynski J
    Struct Chem; 2022; 33(5):1741-1753. PubMed ID: 35692512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic target identification in the novel 2019 coronavirus: insight from homology modeling and blind docking study.
    Durojaye OA; Mushiana T; Uzoeto HO; Cosmas S; Udowo VM; Osotuyi AG; Ibiang GO; Gonlepa MK
    Egypt J Med Hum Genet; 2020; 21(1):44. PubMed ID: 38624499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing FDA-approved compounds to target JAK2 for colon cancer treatment.
    Chandrasekhar B; Gor R; Ramalingam S; Thiagarajan A; Sohn H; Madhavan T
    Discov Oncol; 2024 Jun; 15(1):226. PubMed ID: 38869738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening.
    Kumar S; Jang C; Subedi L; Kim SY; Kim MH
    Sci Rep; 2020 Dec; 10(1):21133. PubMed ID: 33273509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA as an off-target for FDA-approved drugs.
    Fullenkamp CR; Schneekloth JS
    Nat Chem; 2023 Oct; 15(10):1329-1331. PubMed ID: 37697037
    [No Abstract]   [Full Text] [Related]  

  • 17. Virtual high-throughput screening: Potential inhibitors targeting aminopeptidase N (CD13) and PIKfyve for SARS-CoV-2.
    Ruan Z; Tang J; Zeng M; Fan P
    Open Life Sci; 2023; 18(1):20220637. PubMed ID: 37426619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Poly phenolic phytoceutical loaded nano-bilosomes for enhanced caco-2 cell permeability and SARS-CoV 2 antiviral activity': in-vitro and insilico studies.
    Zakaria MY; Abd El-Halim SM; Beshay BY; Zaki I; Abourehab MAS
    Drug Deliv; 2023 Dec; 30(1):2162157. PubMed ID: 36587813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Screening of Novel TMPRSS2 Inhibitors for Treatment of COVID-19.
    Wang S; Fang X; Wang Y
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.
    Gao K; Wang R; Chen J; Cheng L; Frishcosy J; Huzumi Y; Qiu Y; Schluckbier T; Wei X; Wei GW
    Chem Rev; 2022 Jul; 122(13):11287-11368. PubMed ID: 35594413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.